Living Cell raises A$2.8M in NZ for next Parkinson's treatment trial

Living Cell raises A$2.8M in NZ for next Parkinson's treatment trial
Paul McBeth
By Paul McBeth Feb. 17 (BusinessDesk) - Living Cell Technologies, the ASX-listed biotech company with New Zealand-based operations, has raised A$2.8 million from Kiwi investors to help fund the next phase of its product to treat Parkinson's disease.  The Melbourne-headquartered company sold 54.6 million shares at 5.1 Australian cents apiece to a group of New Zealand-resident wholesale investors and plans to raise more money from existing shareholders through a share purchase plan, it said in a statement. The placement was at a 10 percent...